Trade

with

Isis Pharmaceuticals
(NASDAQ: ISIS)
AdChoices
40.39
+0.53
+1.33%
After Hours :
-
-
-

Open

40.11

Previous Close

39.86

Volume (Avg)

300 (1.99M)

Day's Range

40.39-40.39

52Wk Range

22.25-62.66

Market Cap.

-

Dividend Rate ( Yield )

-

Beta

1.48

Shares Outstanding

117.74M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 147.28M

    • Net Income

    • -60.64M

    • Market Cap.

    • -

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -61.04

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.48

    • Forward P/E

    • -34.72

    • Price/Sales

    • 30.77

    • Price/Book Value

    • 12.79

    • Price/Cash flow

    • -312.50

      • EBITDA

      • -37.42M

      • Return on Capital %

      • -11.48

      • Return on Equity %

      • -24.01

      • Return on Assets %

      • -11.48

      • Book Value/Share

      • 3.12

      • Shares Outstanding

      • 117.74M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 60.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -1.15

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 49.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 6.56

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -65.05

            • 39.38

            • Net Profit Margin

            • -61.04

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -57.30

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -24.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.63

              • 0.76

              • Current Ratio

              • 7.00

              • 2.92

              • Quick Ratio

              • 6.28

              • 2.35

              • Interest Coverage

              • -4.00

              • 38.02

              • Leverage Ratio

              • 2.23

              • 2.21

              • Book Value/Share

              • 3.12

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -50.51

                • 188.68

                • P/E Ratio 5-Year High

                • -79.22

                • 634.30

                • P/E Ratio 5-Year Low

                • -7.90

                • 124.82

                • Price/Sales Ratio

                • 30.77

                • 8.72

                • Price/Book Value

                • 12.79

                • 7.95

                • Price/Cash Flow Ratio

                • -312.50

                • 45.45

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -24.01

                        (-7.20)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -11.48

                        (-4.60)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -11.97

                        (-8.30)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.19

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -51.67M
                      Operating Margin
                      -35.08
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -312.50
                      Ownership

                      Institutional Ownership

                      99.10%

                      Top 10 Institutions

                      58.39%

                      Mutual Fund Ownership

                      63.77%

                      Float

                      84.86%

                      5% / Insider Ownership

                      0.26%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Growth Company Fund

                      •  

                        8,678,597

                      • 0.00

                      • 7.37

                      • Bb Biotech AG

                      •  

                        6,706,526

                      • 6.43

                      • 5.70

                      • Artisan Mid Cap Fund

                      •  

                        3,255,236

                      • -1.94

                      • 2.76

                      • AZ InvestEd Ivy Science & Tech Fund

                      •  

                        2,973,300

                      • 21.17

                      • 2.53

                      • Ivy Science and Technology Fund

                      •  

                        2,973,300

                      • 0.00

                      • 2.53

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        2,384,987

                      • 0.00

                      • 2.03

                      • Fidelity® Series Growth Company Fund

                      •  

                        2,088,785

                      • 0.00

                      • 1.77

                      • Vanguard Small Cap Index

                      •  

                        2,045,055

                      • -0.20

                      • 1.74

                      • Waddell & Reed Advisor Science And Techn

                      •  

                        2,030,600

                      • 0.00

                      • 1.73

                      • Legg Mason ClearBridge US Aggressive Gr

                      •  

                        1,917,130

                      • 0.00

                      • 1.63

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        17,549,733

                      • 0.00%

                      • 14.91

                      • ClearBridge Advisors, LLC

                      •  

                        8,239,358

                      • +12.19%

                      • 7.00

                      • Artisan Partners Limited Partnership

                      •  

                        7,571,076

                      • -13.59%

                      • 6.43

                      • Vanguard Group, Inc.

                      •  

                        7,269,544

                      • -6.64%

                      • 6.18

                      • Bellevue Asset Management AG

                      •  

                        6,706,526

                      • +6.43%

                      • 5.70

                      • BB Biotech AG

                      •  

                        6,706,526

                      • +6.43%

                      • 5.70

                      • Waddell & Reed Investment Management Co

                      •  

                        5,363,800

                      • +0.92%

                      • 4.56

                      • BlackRock Fund Advisors

                      •  

                        4,133,698

                      • -5.69%

                      • 3.51

                      • T. Rowe Price Associates, Inc.

                      •  

                        2,766,278

                      • -14.34%

                      • 2.35

                      • State Street Corp

                      •  

                        2,407,618

                      • -0.01%

                      • 2.05

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Speculative Growth

                      Style

                      Mid Growth

                      Isis Pharmaceuticals was incorporated in California in 1989, and in January 1991 the Company changed its state of incorporation to Delaware. The Company is engaged in antisense drug discovery and development, exploiting a novel drug ...morediscovery platform it created to generate a pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. The Company business consists of Drug Discovery and Development operations. Its flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies. ...moreThe Company has a pipeline of 31 drugs in development. Company’s ISIS-TTR and ISIS-SMN drugs are in late stage development. Its partners include Biogen Idec, AstraZeneca and Roche. The Company’s drugs compete with existing therapies for market share. It also competes with specialized pharmaceutical firms and large pharmaceutical companies acting either independently or together with biopharmaceutical companies. The Company is subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.lessless

                      Key People

                      Dr. Stanley T. Crooke,M.D.,PhD

                      CEO/Chairman of the Board/Director/Founder/President

                      Ms. Elizabeth L. Hougen

                      CFO/Senior VP, Divisional

                      D. Wade Walke, PhD

                      Vice President, Divisional

                      Ms. B. Lynne Parshall, J.D.

                      COO/Director/Secretary

                      Mr. Joseph H. Wender

                      Director

                      • Isis Pharmaceuticals

                      • 2855 Gazelle Court

                      • Carlsbad, CA 92010

                      • USA.Map

                      • Phone: +1 760 931-9200

                      • Fax: -

                      • isispharm.com

                      Incorporated

                      1989

                      Employees

                      365

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: